TW202313039A - Pm14用途與方案 - Google Patents

Pm14用途與方案 Download PDF

Info

Publication number
TW202313039A
TW202313039A TW111118548A TW111118548A TW202313039A TW 202313039 A TW202313039 A TW 202313039A TW 111118548 A TW111118548 A TW 111118548A TW 111118548 A TW111118548 A TW 111118548A TW 202313039 A TW202313039 A TW 202313039A
Authority
TW
Taiwan
Prior art keywords
compound
dose
cancer
administered
salt
Prior art date
Application number
TW111118548A
Other languages
English (en)
Chinese (zh)
Inventor
卡門 卡哈特
皮拉爾 拉爾戴利
克利斯提安 費南德茲
阿圖羅 蘇妥
Original Assignee
西班牙商瑪製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西班牙商瑪製藥股份有限公司 filed Critical 西班牙商瑪製藥股份有限公司
Publication of TW202313039A publication Critical patent/TW202313039A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111118548A 2021-05-19 2022-05-19 Pm14用途與方案 TW202313039A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382455 2021-05-19
EP21382455.0 2021-05-19

Publications (1)

Publication Number Publication Date
TW202313039A true TW202313039A (zh) 2023-04-01

Family

ID=76197383

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118548A TW202313039A (zh) 2021-05-19 2022-05-19 Pm14用途與方案

Country Status (11)

Country Link
US (1) US20240277705A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340841A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521122A (cg-RX-API-DMAC7.html)
KR (1) KR20240009437A (cg-RX-API-DMAC7.html)
CN (1) CN117295499A (cg-RX-API-DMAC7.html)
AU (1) AU2022277799A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218171A1 (cg-RX-API-DMAC7.html)
IL (1) IL308389A (cg-RX-API-DMAC7.html)
MX (1) MX2023013715A (cg-RX-API-DMAC7.html)
TW (1) TW202313039A (cg-RX-API-DMAC7.html)
WO (1) WO2022243482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2025228595A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
TW202547503A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之pm14和拓樸異構酶i抑制劑的組合
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
WO2022243482A1 (en) 2022-11-24
MX2023013715A (es) 2024-03-26
CA3218171A1 (en) 2022-11-24
IL308389A (en) 2024-01-01
EP4340841A1 (en) 2024-03-27
AU2022277799A1 (en) 2023-12-21
CN117295499A (zh) 2023-12-26
US20240277705A1 (en) 2024-08-22
KR20240009437A (ko) 2024-01-22
JP2024521122A (ja) 2024-05-28

Similar Documents

Publication Publication Date Title
US20220249528A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US20240277705A1 (en) Dosage regimens for ecubectedin
AU2002342335B2 (en) Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
KR20210084555A (ko) 신경모세포종의 치료에 사용하기 위한 오로라 a 키나제 억제제
JP2015518888A (ja) 腫瘍疾患を治療するための17−アルファ−ヒドロキシラーゼ(c17,20−リアーゼ)インヒビターと特定のpi−3kインヒビターとの組み合わせ
US20240415834A1 (en) Lurbinectedin and atezolizumab combinations
KR20040078123A (ko) 에포틸론 및 대사길항물질을 포함하는 조합물
WO2022101255A1 (en) Lurbinectedin and irinotecan combinations
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるpi3キナーゼ阻害剤とパクリタキセルの組合せ
US11911374B2 (en) Methods and uses for treating cancer
JP2019513767A (ja) マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法
US20060058307A1 (en) Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
WO2025217597A1 (en) A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
WO2022179592A1 (zh) 一种急性髓系白血病的联合治疗药物